Research map: Patterns of Poly(ADP-ribose) Polymerase Inhibitor Use and Overall Survival in United States Veterans with Prostate Cancer

Back to the article

Papers in this map

  1. Olaparib for Metastatic Castration-Resistant Prostate Cancer · Johann Sebastian De Bono · 2020 · 2327 citations · Cited by this paper
  2. CT-Measured Psoas Area Predicts Urinary Incontinence Trajectories and Persistence After Robotic Prostatectomy: A 12-Month Analysis Using the 1-Hour Pad Test · 2026 · Related
  3. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer · Joaquı́n Mateo · 2015 · 2222 citations · Cited by this paper
  4. Age at Diagnosis and Postoperative Outcomes among Men Treated for Prostate Cancer in the U.S. Military Health System · 2026 · Related
  5. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration · Wassim M. Abida · 2020 · 704 citations · Cited by this paper
  6. Circulating Tumor DNA After Radical Cystectomy as a Marker of Minimal Residual Disease in Muscle-Invasive Bladder Cancer: A Literature Review · 2026 · Related
  7. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial · Joaquı́n Mateo · 2019 · 650 citations · Cited by this paper
  8. Delayed Progression-Free Survival Benefit of Belzutifan Versus Everolimus in LITESPARK-005: A Reconstructed Time-to-Event Reanalysis · 2026 · Related
  9. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial · Neeraj Agarwal · 2023 · 535 citations · Cited by this paper
  10. Comparative and Critical Analysis of Immune-based Combinations for First-line Treatment of Metastatic Renal Cell Carcinoma · 2026 · Related
  11. Rucaparib or Physician’s Choice in Metastatic Prostate Cancer · Karim S. Fizazi · 2023 · 450 citations · Cited by this paper
  12. Evaluating Circulating DNA as a Prognostic Biomarker in Bladder Cancer Subtypes: A Preliminary Short Report · 2026 · Related
  13. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial · Fred Saad · 2023 · 320 citations · Cited by this paper
  14. Oncologic Outcomes of Robot-Assisted Radical Cystectomy for Variant Histology Bladder Cancer: A Multi-institutional Propensity Score-Matched Analysis · 2026 · Related
  15. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial · K.N. Chi · 2023 · 220 citations · Cited by this paper
  16. Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications · 2026 · Related
  17. The performance of different propensity score methods for estimating absolute effects of treatments on survival outcomes: A simulation study · Peter C. Austin · 2014 · 198 citations · Cited by this paper
  18. Teratoma-Specific Assay Design Enables Detection of Circulating Tumor DNA in Post-chemotherapy Residual Retroperitoneal Disease · 2026 · Related
  19. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial · Matthew R Smith · 2022 · 192 citations · Cited by this paper
  20. Association Between Proto-Oncogene N-RAS Transcript Level and Overall Survival in Node-Negative Muscle-Invasive Bladder Cancer · 2026 · Related
  21. Survival of African American and non‐Hispanic white men with prostate cancer in an equal‐access health care system · Paul J. Riviere · 2020 · 140 citations · Cited by this paper
  22. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System · Kosj Yamoah · 2022 · 115 citations · Cited by this paper
  23. Characterizing CDK12-Mutated Prostate Cancers · Pasquale Rescigno · 2020 · 107 citations · Cited by this paper
  24. CDK12 -Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade · Michael Thomas Schweizer · 2020 · 96 citations · Cited by this paper
  25. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis · Jaleh Fallah · 2024 · 83 citations · Cited by this paper
  26. Ascertainment of Veterans With Metastatic Prostate Cancer in Electronic Health Records: Demonstrating the Case for Natural Language Processing · Patrick R. Alba · 2021 · 68 citations · Cited by this paper
  27. Rare histological prostate cancer subtypes: Cancer-specific and other-cause mortality · Carolin Siech · 2024 · 23 citations · Cited by this paper
  28. Clinical and pathological features associated with circulating tumor DNA content in real‐world patients with metastatic prostate cancer · Emmanuel S. Antonarakis · 2022 · 22 citations · Cited by this paper
  29. Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer · Kelli Marie Rasmussen · 2023 · 21 citations · Cited by this paper
  30. Comprehensive genomic profiling and treatment patterns across ancestries in advanced prostate cancer: a large-scale retrospective analysis · Smruthy Sivakumar · 2023 · 18 citations · Cited by this paper
  31. Somatic Tumor Next-Generation Sequencing in US Veterans With Metastatic Prostate Cancer · Luca Valle · 2025 · 13 citations · Cited by this paper
  32. Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer · Oliver A. Sartor · 2023 · 5 citations · Cited by this paper
  33. In Reply to “Pathogenic/Likely Pathogenic Somatic CDK12 Mutations in Black Men With Prostate Cancer” · Luca Valle · 2023 · 3 citations · Cited by this paper
  34. How Agent Orange impacts prostate cancer risk, pathology, and treatment outcomes · Awais Paracha · 2024 · 1 citation · Cited by this paper
  35. Untitled · Cited by this paper

Source: OpenAlex (CC0)